Securities code: Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) securities abbreviation: Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) No.: 2022006
Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760)
Record of investor relations activities
□ specific object research □ analyst meeting
□ media interview □ performance briefing
Investor relations □ press conference √ Roadshow
Activity category □ site visit
√ other teleconferences and online strategy meetings of securities companies
The names and surnames of the participants are 110, and there are 399 participants in the organization. See the attached list for details. name
Time: from April 21 to April 22, and from April 24 to April 29, 2022
Mairui building, Keji South 12th Road, high tech Industrial Park, Nanshan District, Shenzhen
Location: Investor’s Office
Name of the person to be received by the listed company from the Secretary of the board of directors Li Wenmei Qian Yuhao, Investor Relations Specialist
1. Interactive questioning
Q: please introduce the admission of SanRui it program by the end of the first quarter of 2022?
A: by the end of the first quarter of 2022:
(1) “Ruizhilian” it solution has achieved a total of 250 signing hospitals, of which more than 30 signing hospitals were added in the first quarter of investor relations, and installed in Huashan Hospital Affiliated to Fudan University, the first hospital affiliated to Suzhou University, Zhongda Hospital Affiliated to Southeast University and other top hospitals;
Rong Introduction (2) “Ruiying cloud + +” has accumulated more than 1600 units, of which more than 300 units were newly installed in the first quarter. The installed hospitals include the First Affiliated Hospital of Nanchang University, the Second Affiliated Hospital of Guilin Medical College, the first hospital of Sanming City, the Affiliated Hospital of North Sichuan Medical College, etc., and led by 7 provincial and municipal Grade-A hospitals, it radiates downward to 75 subordinate branches and grass-roots medical institutions;
(3) The total number of installed hospitals achieved by the “Mairui Zhijian” laboratory it program reached 70, of which 60% were tertiary hospitals, and 10 were newly installed in the first quarter. The installed hospitals include Guangdong maternal and child health hospital, the physical examination center of the first hospital of Lanzhou University, Chengdu Qingbaijiang District People’s Hospital, Zhejiang Taizhou hospital, etc.
Q: since this year, the epidemic situation in some parts of China has been severe. Will the control measures under the epidemic have a negative impact on the development of new medical infrastructure and routine procurement?
A: first of all, the severe epidemic situation not only did not have any negative impact on the construction of China’s new medical base, but strengthened the determination of local governments to speed up the investment in medical construction. Therefore, there was a significant increase in the first quarter of this year, both from the perspective of business opportunities and the number of new reconstruction and expansion projects of hospitals. Secondly, the control measures in areas with repeated epidemics will have a certain negative impact on routine procurement, but the temporarily slowed down equipment procurement will recover soon after the epidemic is alleviated. Third, due to the limitation of routine diagnosis and treatment activities such as outpatient and emergency treatment, hospitalization and surgery in the controlled hospitals, the reagent consumption damaged in the epidemic will not fully recover after the epidemic. Therefore, the negative impact is mainly concentrated in IVD reagent consumption. However, at present, it seems that the impact on IVD production line is limited, mainly for the following three reasons:
(1) The epidemic situation is mainly concentrated in some cities, but the IVD business area layout of the company is balanced, and the consumption of conventional reagents in most areas is not affected by the epidemic control;
(2) In the past two years, the company has launched a number of heavy products in the field of IVD in tertiary hospitals. Among the new installations of blood cell film reader, biochemical and luminous new high-end instruments in the first quarter, tertiary hospitals account for more than 70%. In the future, the proportion of tertiary hospitals in the revenue of IVD production line will be increased rapidly, At the same time, the implementation of Anhui chemiluminescence centralized mining has also brought considerable incremental contributions to the company;
(3) Since this year, the number of routine visits and hospital operations in the international market have fully recovered to the pre epidemic level, resulting in a significant recovery of routine business, including IVD.
Q: the company has launched many heavy products of IVD production line in the past two years. Please introduce the performance of these products?
A: in the second half of 2020, the company launched bc-7500 CRP blood cell analyzer with three-dimensional fluorescence, full-automatic peripheral blood and high-speed CRP detection integrated machine as the marking technology. This product has become the first new product of Mindray with sales exceeding 100 million in the first year of listing in the past 30 years. The of this product in 2021
The final achievement is that the income exceeds 250 million yuan and the installed capacity exceeds 1000 units. The 2020 version of Fudan Top100 hospitals has exceeded 35 and the Top100 maternal and child hospitals have exceeded 46, which has become an important driving force for the blood cell business to reach the top of the domestic market last year. Since this year, the product has gone further on the basis of last year’s strong performance. In the first quarter, the revenue exceeded 100 million yuan and the installed capacity was 400, further consolidating the market position of China’s No. 1 blood cell. It is expected that the annual revenue and installed capacity of this product will continue to achieve high-speed growth year-on-year, and continue the trend of high-end breakthrough.
In the second half of 2021, the company launched automatic cell morphology analyzer MC-80, high-end automatic biochemical analyzer bs-2800m and high-end automatic chemiluminescence immunoanalyzer cl-8000i. In the first quarter of 2021, these three products have achieved dozens of new installations respectively. More importantly, more than 70% of the installations are in tertiary hospitals. The installed capacity of MC-80 tertiary hospitals even reached nearly 90%.
In addition, the company will continue to promote Mindray standardization laboratory and help the hospital improve quality and efficiency under the environment of high-quality development and DRG / Dip payment by providing overall laboratory packaging solutions and “Mindray intelligent inspection” it solutions, while accelerating the improvement of the company’s market share and brand influence.
Q: please introduce the performance highlights of the company’s four emerging businesses in 2021?
A: the four key emerging businesses of the company are animal medicine, minimally invasive surgery, orthopedics and AED. These four businesses almost doubled in 2021 and continued the trend of ultra-high growth in the first quarter of 2022. According to different businesses:
(1) In addition to doubling the growth, the animal medical business also launched heavy products such as veta series anesthesia machine, vetina series hard mirror, bc-75r vet blood cell and Vetus E7 portable ultrasound last year, laying the foundation for sustained high growth in the future;
(2) The starting point of minimally invasive surgery business is mainly hard mirror. Last year, hypixel R1 4K fluorescent hard mirror was launched, and 4K white light hard mirror was installed in batches in many top class III hospitals in China, completing a major breakthrough in high-end customer base;
(3) In last year’s provincial trauma alliance centralized procurement and national joint centralized procurement, the company’s orthopedic business handed over a report card of rapid progress, in which the share of trauma reporting volume increased by 6 times and the share of joint reporting volume increased by 15 times. The company will increase the R & D investment in orthopedic business and expand the automation and intelligence of orthopedics
The scale of production line, continuously optimize the cost structure of orthopedic business, and lay the foundation for becoming the leader of orthopedics in the future;
(4) Thanks to the increasing attention of the public and the government to the popularization and promotion of AED, the AED market has ushered in an outbreak in China, and the years of technology accumulation in defibrillation technology has also made the company a well deserved leader in AED. AED has achieved a large-scale breakthrough in the overseas market, as well as in the overseas market.
For the list of annexes, please refer to the annex list of participants (if any)
Annex: list of participants
Company name company name
Aberdeen standard investments (Hong Kong) Limited Cathay Pacific Life Insurance Co., Ltd
AGF investments Inc Hua’an Fund Management Co., Ltd
Antipodes partners Huabao Fund Management Co., Ltd
Apgasset managementasia Huatai Bairui Fund Management Co., Ltd
AustralianSuper Huatai Securities Co.Ltd(601688)
BNP Paribas Overseas Investment Fund Management Co., Ltd
CIC Intl Hong Kong Ltd Huaxia jiuying Asset Management Co., Ltd
Coatue Management LLC Huili Investment Management Center (limited partnership)
Daiwaasset management huitianfu Fund Management Co., Ltd
East pointasset management Harvest Fund Management Co., Ltd
Fil Investment Management (Shanghai) Company Limited bocom Schroeder Fund Management Co., Ltd
GLG partners LP Jinjian (Shenzhen) Investment Management Center (limited partnership)
Grandeur peak globaladvisors Jingshun Great Wall Fund Management Co., Ltd
Harding loevner LP Morgan Stanley Huaxin Fund Management Co., Ltd
HBM partners Nanjing Shuangan Asset Management Co., Ltd
Hel ved capital ABC Huili Fund Management Co., Ltd
Invescoasia Ltd – Hong Kong ping an Endowment Insurance Co., Ltd
Janchor partners Puyin AXA Fund Management Co., Ltd
Janus Henderson investors Qifeng capital asset management (Hong Kong) Limited
Jericho capital asset management L.P. Qianhai open source Fund Management Co., Ltd
JQAsset Management Company
